Related references
Note: Only part of the references are listed.Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials
Joanna Selfe et al.
PEDIATRIC BLOOD & CANCER (2017)
Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group
Erin R. Rudzinski et al.
PEDIATRIC BLOOD & CANCER (2017)
Outcome, Treatment, and Treatment Failures in Patients Suffering Localized Embryonal Paratesticular Rhabdomyosarcoma Results From the ''Cooperative Weichteilsarkom Studiengruppe'' Trials CWS-86,-91,-96, and-2002P
Guido Seitz et al.
ANNALS OF SURGERY (2016)
Tumour Volume Reduction After Neoadjuvant Chemotherapy Impacts Outcome in Localised Embryonal Rhabdomyosarcoma
Tobias M. Dantonello et al.
PEDIATRIC BLOOD & CANCER (2015)
Impact of Hemiscrotectomy on Outcome of Patients with Embryonal Paratesticular Rhabdomyosarcoma: Results from the Cooperative Soft Tissue Sarcoma Group Studies CWS-86, 91, 96 and 2002P
Guido Seitz et al.
JOURNAL OF UROLOGY (2014)
Classification of Rhabdomyosarcoma and Its Molecular Basis
David M. Parham et al.
ADVANCES IN ANATOMIC PATHOLOGY (2013)
Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Erin R. Rudzinski et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and Austria
C. Rossig et al.
PEDIATRIC BLOOD & CANCER (2013)
Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma
Irene Y. Cheung et al.
PEDIATRIC BLOOD & CANCER (2013)
The Inconvenience of Convenience Cohorts: Rhabdomyosarcoma and the PAX-FOXO1 Biomarker
Abby R. Rosenberg et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Playing Bad Cards Properly: Challenges to Improving Cure Rates in Rhabdomyosarcoma
William H. Meyer
JOURNAL OF CLINICAL ONCOLOGY (2012)
Questionable Universal Validity of PAX3/FOXO1 Fusion Gene Status As Molecular Marker for Improvement of Risk Stratification in Rhabdomyosarcoma Therapy
Sabine Stegmaier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prognostic Value of PAX-FKHR Fusion Status in Alveolar Rhabdomyosarcoma: A Report From the Cooperative Soft Tissue Sarcoma Study Group (CWS)
Sabine Stegmaier et al.
PEDIATRIC BLOOD & CANCER (2011)
Fusion-Negative Alveolar Rhabdomyosarcoma: Modification of Risk Stratification Is Premature
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Diagnosing Alveolar Rhabdomyosarcoma: Morphology Must Be Coupled With Fusion Confirmation
Leonard H. Wexler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Fusion Gene-Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma
Daniel Williamson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
Carola A. S. Arndt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young Adults
Tobias M. Dantonello et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mixed Embryonal/Alveolar Rhabdomyosarcoma of the Prostate: Report of a Case with Molecular Genetic Studies and Literature Review
Jitsupa Treetipsatit et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2009)
Incidence and time trends of soft tissue sarcomas in German children 1985-2004 -: A report from the population-based German Childhood Cancer Registry
Thomas Weihkopf et al.
EUROPEAN JOURNAL OF CANCER (2008)
Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma
Tobias M. Dantonello et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS-96 trial
Thomas Klingebiel et al.
PEDIATRIC BLOOD & CANCER (2008)
Use of a novel FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of alveolar rhabdomyosarcoma
Jun Nishio et al.
LABORATORY INVESTIGATION (2006)
Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world
AT Deyrup et al.
HISTOPATHOLOGY (2006)
Treatment for soft tissue sarcoma in childhood and adolescence Austrian results within the CWS 96 study
D Modritz et al.
WIENER KLINISCHE WOCHENSCHRIFT (2005)
Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma? The experience of Italian and German soft tissue sarcoma cooperative group
A Ferrari et al.
PEDIATRIC BLOOD & CANCER (2004)
Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: Results of the malignant mesenchymal tumors studies (MMT 84 and MMT 89) of the international society of pediatric oncology
RJ Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease
WM Crist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Sclerosing, pseudovascular rhabdomyosarcoma in adults - Clinicopathological and immunohistochemical analysis of three cases
T Mentzel et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2000)